Similar to the combination of ICIs and intravenous anti-VEGF agents, ICIs and TKIs could have synergistic effects, as molecular target agents could collectively block the signalling from various growth factors and affect immune effectors, as well as the tumour vasculature [25,26]. The gene discussed is VEGFA; the disease is neoplasm.